Carmot Therapeutics Inc.
Orally available small molecule GLP-1 receptor agonists for type 2 diabetes treatment
- Sector
- Biotech
- Headquarters
- CA
- Founded
- 2008
- Latest Form D
- $150M, Jun 2023
- Total capital
- $353M
- Federal grants
- $3.1M
- 6 awards · 2010–2012
- 6.0× sector median 1 award
- Private capital raised
- $350M
- 6 Form D · last Jun 2023
- 41 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2022
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$150M
- Private capital raisedForm D · SEC · 5th filing$161M
- Private capital raisedForm D · SEC · 4th filing$26.3M
- Private capital raisedForm D · SEC · 3rd filing$10.8M
- Federal grantHealth and Human S · Phase I · Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o$323K
- Federal grantHealth and Human S · Phase I · Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o$219K
- Private capital raisedForm D · SEC · 2nd filing$500K
- Private capital raisedForm D · SEC · 1st filing$1.5M
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase I · A novel approach to discover selective small molecule inhibitors of FABP4 and FAB$300K
- Federal grantHealth and Human S · Phase I · Discovery of small molecule drug candidates that disrupt the NEMO/IKK signaling c$299K
- Federal grantHealth and Human S · Phase II · Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of$988K
- Federal grantHealth and Human S · Phase II · Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of$924K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Daniel A. ErlansonResearcherExecutive Officer, DirectorLinked by $300K in grants as PI
- Stig K. HansenResearcherExecutive Officer, DirectorLinked by $2.2M in grants as PI
- Aetna Wun TrombleyDirectorNamed in SEC Form D filings
- Aetna Wun K. TrombleyDirectorNamed in SEC Form D filings
- Anne Phillips, M.D.DirectorNamed in SEC Form D filings
- Dave K. GoeddelDirectorNamed in SEC Form D filings
Show all 15 people
- Heather TurnerExecutive Officer, DirectorNamed in SEC Form D filings
- Larry K. LaskyDirectorNamed in SEC Form D filings
- Magnus K. PerssonDirectorNamed in SEC Form D filings
- Peter K. SvennilsonDirectorNamed in SEC Form D filings
- Stig K. Hansen, Ph.D.DirectorNamed in SEC Form D filings
- Stig K. Hansen, Ph.D.DirectorNamed in SEC Form D filings
- Tim KutzkeyDirectorNamed in SEC Form D filings
- Tim K. KutzkyDirectorNamed in SEC Form D filings
- Timothy GarnettDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingModulators Of G-protein Coupled ReceptorsUSPTOApplication 19091745
- PendingSynthesis of GLP-1R/GIPR Agonists and Precursors ThereofUSPTOApplication 19429930
- GrantedGpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseUSPTOUS 12,459,929
Show all 40 patent records
- Modulators Of G-protein Coupled ReceptorsJun 25, 2026 · Application 19091745Pending
- Synthesis of GLP-1R/GIPR Agonists and Precursors ThereofApr 30, 2026 · Application 19429930Pending
- Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseNov 4, 2025 · US 12,459,929Granted
- Modulators Of G-protein Coupled ReceptorsApr 22, 2025 · US 12,281,149Granted
- Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseMar 20, 2025 · Application 18632736Pending
- Oxazole, Oxadiazole, And Indole Derivatives For The Inhibition Of USP28Dec 26, 2024 · Application 18703124Pending
- Treatment of Adults With Overweight or Obesity With or Without Weight-Related ComorbiditiesNov 28, 2024 · Application 18670592Pending
- Modulators of G-Protein Coupled ReceptorsNov 21, 2024 · Application 18777223Pending
- Treatment of Diabetes MellitusNov 7, 2024 · Application 18644041Pending
- Benzimidazoyl GLP-1 Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseAug 8, 2024 · Application 18558647Pending
- Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseAug 1, 2024 · Application 18262956Pending
- Modulators Of G-protein Coupled ReceptorsNov 9, 2023 · Application 18087063Pending
- Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseMar 23, 2023 · Application 17586751Pending
- N-CYANO-7-AZANORBORNANE Derivatives And Uses ThereofFeb 7, 2023 · US 11,572,374Granted
- Modulators of G-Protein Coupled ReceptorsDec 27, 2022 · US 11,535,660Granted
- Benzimidazoyl GLP-1 Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseDec 15, 2022 · Application 17736070Pending
- Synthesis Of GLP-1R/GIPR Agonists And Precursors ThereofApplication PCTUS2024035155Pending
- Method of Treating Diabetes Using A GLP-1 Receptor ModulatorApplication 63659682Pending
- Treatment Of Adults With Overweight Or Obesity With Or Without Weight-related ComorbiditiesApplication PCTUS2024030441Pending
- Treatment of Adults With Overweight or Obesity With or Without Weight-Related ComorbiditiesApplication 63648158Pending
- Treatment Of Diabetes MellitusApplication PCTUS2024025885Pending
- Hybrid Peptide Compounds Having A Terminal SubstituentApplication 63609340Pending
- Hybrid Peptide Compounds Having A Substituted Tryptophan ResidueApplication 63609336Pending
- Hybrid Peptide Compounds Having A Modified Lysine ResidueApplication 63609335Pending
- Treatment of Diabetes MellitusApplication 63590388Pending
- Treatment of Adults With Overweight or Obesity With or Without Weight-Related ComorbiditiesApplication 63590395Pending
- GLP-1 Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication 18240763Pending
- N-heterocylic Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication PCTUS2023071000Pending
- Treatment of Overweight or Obese Adults With or Without Type 2 Diabetes MellitusApplication 63511858Pending
- Treatment of Diabetes MellitusApplication 63509743Pending
- Synthesis of GLP-1R/GIPR Agonists and Precursors ThereofApplication 63509754Pending
- Treatment of Overweight or Obese Adults With or Without Type 2 Diabetes MellitusApplication 63503492Pending
- Treatment of Type 1 Diabetes MellitusApplication 63497737Pending
- Oxazole, Oxadiazole, And Indole Derivatives For The Inhibition Of USP28Application PCTUS2022047438Pending
- N-heterocylic Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication 63392857Pending
- Modulators Of G-protein Coupled ReceptorsApplication PCTUS2022029305Pending
- Benzimidazoyl GLP-1 Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication PCTUS2022027535Pending
- Gpcr Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication PCTUS2022014156Pending
- Benzimidazoyl GLP-1 Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication 63282686Pending
- GLP-1 Receptor Agonists, Pharmaceutical Compositions Comprising The Same, And Methods For Their UseApplication 63274893Pending
Related companies, and why
- ADARx PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- COARE HOLDINGS INCSimilar federal contract value in Biotech · null in contracts
- Reservoir Neuroscience, Inc.Similar federal contract value in Biotech · null in contracts
- IGM BiosciencesSimilar federal contract value in Biotech · null in contracts
- REVOPSIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Elevian, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .